EICHORCondition: Migraine · Sponsor: Amgen
This study will evaluate the efficacy and safety of erenumab in migraine prevention in children (6 to \<12 years) and adolescents (12 to \<18 years) with episodic migraine. The study hypothesis is that in pediatric participants with episodic migraine, the combined erenumab dose group has a greater reduction from baseline to week 9 through week 12 (month 3) in monthly migraine days (MMDs) when compared with placebo in the double-blind treatment phase (DBTP).
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| Paradigm Clinical Research Center Inc | San Diego, California, United States | — |
| Childrens Hospital Colorado | Aurora, Colorado, United States | — |
| Colorado Springs Neurological Associates | Colorado Springs, Colorado, United States | — |
| New England Institute for Clinical Research | Stamford, Connecticut, United States | — |
| Childrens National Health System | Washington D.C., District of Columbia, United States | — |
| Northwest Florida Clinical Research Group Limited Liability Company | Gulf Breeze, Florida, United States | — |
| Nicklaus Childrens Hospital | Miami, Florida, United States | — |
| Pediatric Epilepsy and Neurology Specialists | Tampa, Florida, United States | — |
| TrueBlue Clinical Research | Tampa, Florida, United States | — |
| Premiere Research Institute | West Palm Beach, Florida, United States | — |
| Rare Disease Research Center Pediatrics | Atlanta, Georgia, United States | — |
| CenExel iResearch, LLC | Savannah, Georgia, United States | — |
+ 107 more locations — full list on the registry record.
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03836040